Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06964438

Postoperative Electrical Muscle Stimulation Two

Postoperative Electrical Muscle Stimulation Two — Recruiting • Non-phase study • Oncology • NCT06964438.

📅 17 Jun 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06964438
Sponsor
University of Nottingham
Start
2025-06-05
ClinicaliQ Trial Snapshot
  • Postoperative Electrical Muscle Stimulation Two — Recruiting • Non-phase study • Oncology • NCT06964438.
  • What is being tested: Electrical muscle stimulation (EMS) applied postoperatively to prevent or reduce skeletal muscle atrophy in patients experiencing immobility or inactivity following surgery.
  • Patient eligibility overview: The trial targets postoperative patients at risk of muscle loss due to bed rest, physical inactivity, or disease-related factors, though specific inclusion/exclusion criteria would determine exact patient populations studied.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery. The investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery.…

Eligibility Snapshot
  • : * Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting) * MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery * Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital * Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery * Basic conversational spoken English language * Ability to give informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 09 Sep 2026
The International Agency for Research on Cancer (IARC) has classified drinking "very hot" beverages (>65°C) as a probable carcinogen (Group 2A), associated…
View brief →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 08 Sep 2026
The International Agency for Research on Cancer has classified drinking "very hot" beverages (above 65°C) as probably carcinogenic, with repeated thermal injury…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →